相似文献
1
A metabolic link between the urea cycle and cancer cell proliferation.
Mol Cell Oncol. 2016 Feb 18;3(2):e1127314. doi: 10.1080/23723556.2015.1127314. eCollection 2016 Mar.
2
Diversion of aspartate in ASS1-deficient tumours fosters de novo pyrimidine synthesis.
Nature. 2015 Nov 19;527(7578):379-383. doi: 10.1038/nature15529. Epub 2015 Nov 11.
3
ASS1 and ASL suppress growth in clear cell renal cell carcinoma via altered nitrogen metabolism.
Cancer Metab. 2021 Dec 3;9(1):40. doi: 10.1186/s40170-021-00271-8.
4
Extracellular vesicles from human liver stem cells restore argininosuccinate synthase deficiency.
Stem Cell Res Ther. 2017 Jul 27;8(1):176. doi: 10.1186/s13287-017-0628-9.
5
Naturally-occurring spinosyn A and its derivatives function as argininosuccinate synthase activator and tumor inhibitor.
Nat Commun. 2021 Apr 15;12(1):2263. doi: 10.1038/s41467-021-22235-8.
6
ASS1 metabolically contributes to the nuclear and cytosolic p53-mediated DNA damage response.
Nat Metab. 2024 Jul;6(7):1294-1309. doi: 10.1038/s42255-024-01060-5. Epub 2024 Jun 10.
7
Acid-Induced Downregulation of ASS1 Contributes to the Maintenance of Intracellular pH in Cancer.
Cancer Res. 2019 Feb 1;79(3):518-533. doi: 10.1158/0008-5472.CAN-18-1062. Epub 2018 Dec 20.
8
PRMT7 Interacts with ASS1 and Citrullinemia Mutations Disrupt the Interaction.
J Mol Biol. 2017 Jul 21;429(15):2278-2289. doi: 10.1016/j.jmb.2017.05.026. Epub 2017 Jun 3.
9
Oncogenic KRAS Induces Arginine Auxotrophy and Confers a Therapeutic Vulnerability to SLC7A1 Inhibition in Non-Small Cell Lung Cancer.
Cancer Res. 2024 Jun 14;84(12):1963-1977. doi: 10.1158/0008-5472.CAN-23-2095.
10
Kinetic mutations in argininosuccinate synthetase deficiency: characterisation and in vitro correction by substrate supplementation.
J Med Genet. 2016 Oct;53(10):710-9. doi: 10.1136/jmedgenet-2016-103937. Epub 2016 Jun 10.
引用本文的文献
1
Hyaluronic Acid Influences Amino Acid Metabolism via Differential L-Type Amino Acid Transporter 1 Expression in the U87-Malignant Glioma Cell Line.
Adv Nanobiomed Res. 2024 Dec;4(12). doi: 10.1002/anbr.202400107. Epub 2024 Sep 2.
2
Identification of Causal Plasma Proteins in Hepatocellular Carcinoma via Two-Sample Mendelian Randomization and Integrative Transcriptomic‒Proteomic Analysis.
Cancer Res Commun. 2025 Mar 1;5(3):433-443. doi: 10.1158/2767-9764.CRC-24-0553.
3
Disturbances in Nitric Oxide Cycle and Related Molecular Pathways in Clear Cell Renal Cell Carcinoma.
Cancers (Basel). 2023 Dec 11;15(24):5797. doi: 10.3390/cancers15245797.
4
Engineering the glioblastoma microenvironment with bioactive nanoparticles for effective immunotherapy.
RSC Adv. 2023 Oct 27;13(45):31411-31425. doi: 10.1039/d3ra01153d. eCollection 2023 Oct 26.
5
Datamining approaches for examining the low prevalence of N-acetylglutamate synthase deficiency and understanding transcriptional regulation of urea cycle genes.
J Inherit Metab Dis. 2024 Nov;47(6):1175-1193. doi: 10.1002/jimd.12687. Epub 2023 Nov 5.
6
, , and (Citrin) at the Crossroads of Arginine and Pyrimidines Metabolism in Tumor Cells.
Int J Mol Sci. 2023 Apr 4;24(7):6754. doi: 10.3390/ijms24076754.
7
Identification and Characterization of Metabolic Subtypes of Endometrial Cancer Using a Systems-Level Approach.
Metabolites. 2023 Mar 9;13(3):409. doi: 10.3390/metabo13030409.
8
Renal Cell Carcinoma as a Metabolic Disease: An Update on Main Pathways, Potential Biomarkers, and Therapeutic Targets.
Int J Mol Sci. 2022 Nov 18;23(22):14360. doi: 10.3390/ijms232214360.
9
Clinical and biochemical footprints of inherited metabolic diseases. VIII. Neoplasias.
Mol Genet Metab. 2022 Jun;136(2):118-124. doi: 10.1016/j.ymgme.2022.03.011. Epub 2022 Mar 28.
10
Comprehensive Metabolic Profiling of MYC-Amplified Medulloblastoma Tumors Reveals Key Dependencies on Amino Acid, Tricarboxylic Acid and Hexosamine Pathways.
Cancers (Basel). 2022 Mar 3;14(5):1311. doi: 10.3390/cancers14051311.
本文引用的文献
1
Diversion of aspartate in ASS1-deficient tumours fosters de novo pyrimidine synthesis.
Nature. 2015 Nov 19;527(7578):379-383. doi: 10.1038/nature15529. Epub 2015 Nov 11.
2
Metabolic dysregulation in monogenic disorders and cancer - finding method in madness.
Nat Rev Cancer. 2015 Jul;15(7):440-8. doi: 10.1038/nrc3949. Epub 2015 Jun 18.
3
Arginine deiminase resistance in melanoma cells is associated with metabolic reprogramming, glucose dependence, and glutamine addiction.
Mol Cancer Ther. 2013 Nov;12(11):2581-90. doi: 10.1158/1535-7163.MCT-13-0302. Epub 2013 Aug 26.
4
Epigenetic status of argininosuccinate synthetase and argininosuccinate lyase modulates autophagy and cell death in glioblastoma.
Cell Death Dis. 2013 Jan 17;4(1):e458. doi: 10.1038/cddis.2012.197.
5
Integrative genome comparison of primary and metastatic melanomas.
PLoS One. 2010 May 24;5(5):e10770. doi: 10.1371/journal.pone.0010770.
6
Reduced argininosuccinate synthetase is a predictive biomarker for the development of pulmonary metastasis in patients with osteosarcoma.
Mol Cancer Ther. 2010 Mar;9(3):535-44. doi: 10.1158/1535-7163.MCT-09-0774. Epub 2010 Feb 16.
7
Global reconstruction of the human metabolic network based on genomic and bibliomic data.
Proc Natl Acad Sci U S A. 2007 Feb 6;104(6):1777-82. doi: 10.1073/pnas.0610772104. Epub 2007 Jan 31.
Zotero 插件